Trial Profile
An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 14 Jun 2023 Results of sub-group analysis assessing long-term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse, published in the Headache.
- 01 May 2022 Results of subgroup analysis and post hoc analysis assessing long-term efficacy and safety of erenumab in group of patients with chronic migraine in whom prior preventive treatments had failed and never failed, published in the Headache
- 20 Dec 2021 Results of post-hoc secondary analysis of NCT01952574, NCT02456740, NCT02483585, NCT02066415, and NCT02174861 assessing the efficacy and safety profiles of erenumab in patients with migraine with aura, published in the JAMA Neurology.